Advertisement

---

ABBOTT

Abbott Announces New Test to Help Doctors Determine Personalized Treatment Path for Patients with Hepatitis C

[2013-06-20] - First U.S. Food and Drug Administration (FDA)-approved hepatitis C genotyping test is now available in the U.S. to help physicians improve patient care.


Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend

[2013-06-14] -


Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

[2013-06-11] -


Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

[2013-06-11] - - Trial to Study the Innovative "Dissolving" Heart Device Compared to Abbott's Market-Leading Drug Eluting Stents in Patients with Coronary Artery Disease in Japan


Abbott to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference

[2013-06-10] -


Abbott to Present at William Blair 33rd Annual Growth Stock Conference

[2013-06-04] -


Two Real-World European Studies of Abbott's Minimally Invasive MitraClip® Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation

[2013-06-04] - - Findings Published in the Journal of the American College of Cardiology Demonstrate Significant Improvements in Day-to-Day Quality of Life
- Study in EuroIntervention Shows Similar Benefits in Both Elderly and Younger Patients


Two Real-World European Studies of Abbott's Minimally Invasive MitraClip® Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation

[2013-06-04] -


Abbott Previews Next-Generation Blood Screening Prototype during International Society of Blood Transfusion Meeting

[2013-06-03] -


Abbott to Present at Goldman Sachs 34th Annual Global Healthcare Conference

[2013-05-31] -


Abbott to Present at Deutsche Bank 38th Annual Health Care Conference

[2013-05-22] -


Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

[2013-05-21] -


Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

[2013-05-21] - - XIENCE Xpedition™ 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents
- Has the Potential to Reduce Overall Procedural Costs
- Very Long Lesions Most Often Seen in Patients with Diabetes


Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes

[2013-05-09] -


Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes

[2013-05-09] -


Abbott to Present at UBS Global Healthcare Conference

[2013-05-08] -


1 - 2
Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers